|
||
Articles |
vβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes



Division of Hematology-Oncology, Cornell University Medical College, New York 10021
| Abstract |
|---|
|
|
|---|
vβ5 integrin and CD36. Upon maturation, these receptors and, in turn, the phagocytic capacity of DCs, are downmodulated. Macrophages engulf apoptotic cells more efficiently than DCs, and although they express many receptors that mediate this uptake, they lack the
vβ5 integrin. Furthermore, in contrast to DCs, macrophages fail to cross-present antigenic material contained within the engulfed apoptotic cells. Thus, DCs use unique pathways for the phagocytosis, processing, and presentation of antigen derived from apoptotic cells on class I major histocompatibility complex. We suggest that the
vβ5 integrin plays a critical role in the trafficking of exogenous antigen by immature DCs in this cross-priming pathway.
Key Words: dendritic cells phagocytosis CD36 integrins cross-presentation
Abbreviations used: Ann V, Annexin V; DC, dendritic cell; MCM, monocyte-conditioned medium; PI, propidium iodide; PS, phosphatidylserine.
poptosis triggers a distinct sequence of events characterized by the expression of phosphatidylserine (PS)1 on the cell surface (1), DNA fragmentation or laddering (2), and the release of membrane-bound cell fragments called apoptotic blebs and bodies (3, 4). Apoptotic cells and bodies are phagocytosed via various receptors that recognize PS and other undefined ligands unique to the surface of apoptotic material (1). In this way, dying cells, which contain potentially inflammatory factors, are rapidly cleared by neighboring cells, scavenger cells, or macrophages without inducing an inflammatory response (5, 6).
We have recently demonstrated that human dendritic cells (DCs) acquire antigens from apoptotic cells and stimulate antigen-specific class I–restricted CD8+ T cells (7). Apoptotic death is a critical trigger for this pathway, as antigen from necrotic cells is not presented on MHC I (7). This in vitro model for cross-priming may be akin to the in vivo phenomenon in which antigens derived from MHC-mismatched donor cells are cross-presented on host APC's class I MHC (8–10). This event is potentially significant in the maintenance of tolerance to tissue-specific antigens and the induction of immunity to antigens that may not access the endogenous MHC class I pathway of a professional APC.
Here, we investigate the developmental stage and receptors used by DCs for the efficient phagocytosis of apoptotic cells in this exogenous pathway. DCs undergo a differentiation process that includes immature' and mature' stages (11). Monocytes that have been cultured in GM-CSF and IL-4 develop into immature DCs. These cells are analogous to peripheral tissue DCs. Immature DCs are characterized by high endocytic and macropinocytic activity (12–16) and low expression of accessory signals for T cell activation (11, 17). Maturation of DCs, induced by antigen, cytokines, or signaling molecules (e.g., LPS, monocyte-conditioned medium [MCM], ceramide, CD40L, TNF-
Preparation of Cells.
Antibodies.
Induction of Apoptotic Death.
Phagocytosis of Apoptotic Cells.
Phagocytosis of Latex Beads.
Immunofluorescence.
Assay for Cross-priming of Apoptotic Cells.
Reverse Transcriptase PCR.
, and PGE2 [12, 13, 18– 22]) is associated with the downregulation of antigen uptake, but an enhancement of the T cell stimulatory capacity. By using a modified FACS®-based method for detecting phagocytic uptake, we compared immature DCs, mature DCs, and macrophages for their capacity to phagocytose apoptotic cells and cross-present viral antigens to CTLs (23). We report that immature DCs are specialized in their ability to cross-present antigen and that the phagocytosis of apoptotic cells correlates with the use of a unique receptor profile.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results
Discussion
References
Media.
RPMI 1640 supplemented with 20 µg/ml of gentamicin (GIBCO BRL, Gaithersburg, MD), 10 mM Hepes (Mediatech, Herndon, VA), and either 1% human plasma, 5% pooled human serum (c-Six Diagnostics, Mequon, WI), or 5% single donor human serum was used for DC preparation, cell isolation, and culture conditions (18, 24).
PBMCs, DCs, macrophages, and T cells were prepared as previously described (18, 19, 24). In brief, peripheral blood was obtained from normal donors in heparinized syringes and PBMCs were isolated by sedimentation over Ficoll-Hypaque (Amersham Pharmacia Biotech, Piscataway, NJ). T cell–enriched and T cell–depleted fractions were prepared by rosetting with neuraminidase-treated sheep red blood cells (24). Immature DCs were prepared from the T cell–depleted fraction by culturing cells in the presence of GM-CSF and IL-4 for 7 d. 1,000 U/ml of GM-CSF (Immunex Corp., Seattle, WA) and 500–1,000 U/ml of IL-4 (Schering-Plough Corp., Kenilworth, NJ) were added to the cultures on days 0, 2, and 4. To generate mature DCs, the cultures were transferred to fresh wells on day 7 and MCM was added for an additional 3–4 d (18, 19). At day 7, >95% of the cells were CD14–CD83–HLA-DRlo DCs. On days 10–11, 80–100% of the cells were of the mature CD14–CD83+ HLA-DRhi phenotype. FACSort® (Becton Dickinson, San Jose, CA) was used to generate highly pure populations of immature and mature DCs, based on their CD83– and CD83+ phenotypes, respectively. Macrophages were isolated from T cell–depleted fractions by plastic adherence for 1 h. After 24 h, cells were removed from the plates and placed in Teflon beakers for 3–9 d. T cells were further purified from the T cell–enriched fraction by removing contaminating monocytes, NK cells, and B cells (24).
Antibodies to the following proteins were used: CD8-PE, CD14-PE, HLA-DR–PE, HLA-DR–biotin (Becton Dickinson), IgG2b (clone 6603001; Coulter Corp., Hialeah, FL), CD8 (CRL 8014; American Type Culture Collection, Rockville, MD), CD83 (clone HB15a; Coulter Corp.), MHC I (W6/ 32, ATCC clone HB95), CD36 (clone FA6; obtained from the fifth international workshop on leukocyte differentiation antigens),
v (clone CLB-706, Chemicon International, Inc., Temecula, CA; clone 69.6.5, Coulter Corp.), β1 (clone 6S6; Chemicon International, Inc.), β3 (clone SZ21, Coulter Corp.; clone RUU-PL 7F12, Becton Dickinson), β5 (clone B5-IVF2; Upstate Biotechnology, Inc., Lake Placid, NY),
vβ3 (clone 23C6; PharMingen, San Diego, CA),
vβ5 (clone P1F6; Chemicon International, Inc.), CD71 (Dako Corp., Carpinteria, CA), mannose receptor (clone 3.2PB1; a gift from A. Lanzavecchia, Basel Institute, Sweden), and influenza nucleoprotein (ATCC clone HB85).
Monocytes were infected with influenza virus in serum-free RPMI. These cells undergo viral-induced apoptotic death within 6–8 h. Cell death was confirmed using the Early Apoptosis Detection kit (Kayima Biomedical Co., Seattle, WA [7]). As previously described, cells are stained with Annexin V–FITC (Ann V) and propidium iodide (PI). Early apoptosis is defined by Ann V+/PI– staining as determined by FACScan® (Becton Dickinson). To ensure that we were studying the uptake of early apoptotic cells, the kinetics of death were carefully worked out. 5–8 h after infection, monocytes first externalize PS on the outer leaflet of their cell membrane, as detected with Ann V. By 8–10 h, these cells were TUNEL (Tdt-mediated dUTP- biotin nick-end labeling) positive. It was not until 24–36 h that the majority of the monocyte population included trypan blue into the cytoplasm, an indicator of secondary necrosis (Albert, M.L., and N. Bhardwaj, unpublished data, references 25, 26). HeLa cells were triggered to undergo apoptosis using a 60 UVB lamp (Derma Control Inc.), calibrated to provide 2 mJ/cm2/s. The kinetics of cell death in these cells has been defined previously (4).
Monocytes and HeLa cells were dyed red using PKH26-GL (Sigma Biosciences, St. Louis, MO), and induced to undergo apoptosis by influenza infection and UVB irradiation, respectively. After 6–8 h, allowing time for the cells to undergo apoptosis, they were cocultured with phagocytic cells that were dyed green using PKH67-GL (Sigma Biosciences), at a ratio of 1:1. Macrophages were used 3–6 d after isolation from peripheral blood; immature DCs were used on days 6–7 of culture; and mature DCs were used on days 10–11. Where direct comparison of cells was needed, cells were prepared from the same donor on different days. In blocking experiments, the immature DCs were preincubated in the presence of 50 µg/ml of various mAbs for 30 min before the establishment of cocultures. After 45–120 min, FACScan® analysis was performed and double positive cells were enumerated.
Immature DCs were preincubated at 37°C with mAbs specific for
v and
vβ5. 106 cells were then cultured with 5 x 107 red fluorescent microspheres (diameter 1 µm, 2.5% solids, carboxylate-modified latex; Sigma Chemical Co.) for varying periods of time. Alternatively, the cells were maintained at 4°C. At the end of the assay, cells were separated from unengulfed beads by density gradient centrifugation and analyzed by FACScan® analysis (27).
Cells were adhered to Alcian blue (Sigma Chemical Co.) treated coverslips and fixed using 100% acetone. Cells were stained with antiinfluenza nucleoprotein antibody (HB85; American Type Culture Collection) and Texas red conjugated goat anti–mouse IgG (Jackson ImmunoResearch Labs., Inc., West Grove, PA). This was followed by staining with biotinylated anti–HLA-DR (Becton Dickinson) followed by FITC-conjugated streptavidin (Jackson ImmunoResearch). Cells were visualized using a Zeiss Axioplan2 microscope (Carl Zeiss, Inc., Thornwood, NY).
Various APC populations were prepared from HLA-A2.1+ donors as described above. Mature DCs were further purified by labeling with the DC-restricted marker CD83, followed by cell sorting on the FACSort®. Immature DCs were CD14– and sorted by FACSort® as a CD83– population. Mature macrophages were generated by culturing an adherent mononuclear cell fraction in a Teflon beaker for 9 d. These APC populations were cocultured with HLA-A2.1– influenza-infected monocytes. After 12 h, the APCs were loaded with Na51CrO4 and used as targets for influenza-specific CTLs in a standard 51Cr-release assay (7, 24). Specific lysis indicates that the APC had cross-presented antigenic material derived from the apoptotic cell, leading to the formation of specific peptide–MHC class I complexes on its surface. Specific lysis = (% killing of APCs cross-presenting influenza-infected monocytes) – (% killing of APCs cross-presenting uninfected monocytes). Background lysis ranged from 0 to 8%. Controls included influenza-infected and uninfected mature DCs, immature DCs, and macrophages. The HLA-A2.1– monocytes used as a source of apoptotic material were also tested as targets to demonstrate the absence of lysis when using a mismatched target. For the control targets, specific lysis = (% killing of influenza-infected APCs) – (% killing of uninfected APCs). Background lysis ranged from 0 to 5%. Maximal influenza-specific killing was determined using T2 cells (a TAP–/–HLA-A2.1+ class II– cell line) pulsed for 1 h with 1 µM of the immunodominant influenza matrix peptide, GILGFVFTL, as targets (28). Responses varied from 25 to 60% as a function of the individual's prior exposure to influenza.
RNA was purified from highly purified sorted cell populations of immature and mature DCs as described above. Messenger RNA for β3, β5, and CD36 were identified using a one-step reverse transcriptase PCR reaction (Titan kit; Boehringer Mannheim, Indianapolis, IN). The forward primer 5'-TGAGAAGTGCCCCTGCCC was used for both β3 and β5. The reverse primers 5'-GTTGGCTGTGTCCCATTTTGCT and 5'-TTGTAGGATTTGTGAACTTG were used for β3 and β5 to obtain 438- and 509-bp products, respectively (primer sequences were provided by S. Silletti, Scripps, San Diego, CA). The forward primer 5'-GGGAATTCATATGAAATCATAAAAGCAACAAACAT and the reverse primer 5'-CGGAATTCTACATTTCACTTCCTCATTTTCTG for CD36 yielded a product of 392 bp (29). The reverse transcriptase reaction was carried out for 30 min at 56°C followed by 30 cycles of amplification. After 30 cycles of PCR the samples were visualized on an agarose gel.
![]()
Results
Top
Abstract
Materials and Methods
Results
Discussion
References
Immature DCs Efficiently Phagocytose Apoptotic Cells.
Based on previous observations that immature DCs are the cells responsible for capturing antigen (11), we predicted that apoptotic cells would be engulfed best by immature DCs. To test this hypothesis, we established a phagocytosis assay that allowed us to visually detect the uptake of apoptotic cells, and compare the phagocytic capacity of immature DCs, mature DCs, and macrophages. In brief, immature DCs were prepared by culturing a T cell–depleted fraction from peripheral blood in the presence of IL-4 and GM-CSF. Mature DCs were generated with the addition of MCM and these cells expressed the cell surface DC-restricted maturation marker CD83 (18, 19, 30). Macrophages were prepared by culturing a plastic adherent cell population in Teflon beakers for 3–9 d. As a source of apoptotic cells, we used influenza-infected monocytes (7); virus infection induces apoptotic death in these cells within 6–10 h (7, 25, 26). Monocytes were first infected with influenza virus as previously described (24), then dyed red using PKH-26 (Sigma Biosciences). After 6–8 h, the various APCs were dyed green using the fluorescent cell linker compound PKH67-GL (Sigma Biosciences) and cocultured with the apoptotic cells at a ratio of 1:1. After 2 h at 37°C, cocultures of cells were analyzed by FACScan® analysis, allowing for quantification of phagocytic uptake as double positive cells. 80% of the macrophages, 50% of the immature DCs, and <10% of the mature DCs engulfed the apoptotic monocytes after 2 h of coculture (Fig. 1 A). The smear of double positive cells (PKH67-labeled APCs that engulfed the PKH26-labeled apoptotic cells) indicates that both apoptotic bodies and whole apoptotic cells served as food' for the phagocytic cell (Fig. 1, iii, vi, and ix). Note that as the forward scatter of the APCs increased and the setting of the FACS® shifted, the dying monocytes were excluded from the established region (Fig. 1, ii, v, and viii). Maximal uptake by all APC populations was achieved within 2–4 h and partially depended upon the source of apoptotic cell used (Fig. 1 B and data not shown). Given this kinetic data, we believe that macrophages and DCs engage and internalize dying cells while still displaying features of early apoptotic cell death. This data also demonstrates that it is the immature DC that preferentially acquires apoptotic material compared with the mature DC. The source of apoptotic cells was not critical, since we obtained similar results with UVB-irradiated HeLa cells (see Fig. 7, and data not shown).
|
|
|
|
|
Notably, macrophages that efficiently phagocytose apoptotic cells (Fig. 1 A) did not cross-present antigens to CTLs (Fig. 4 B). Presumably, the engulfed material is degraded, not cross-presented, on MHC I. This profound difference between the DC and macrophage populations is supported by our previous findings that macrophages do not cross-present antigens from apoptotic cells during the induction phase of a class I–restricted antigen-specific T cell response. In fact, when put into culture with DCs in a competition assay, they sequester the apoptotic material and abrogate the CTL response (7).
Immature DCs Can Be Distinguished from Macrophages by Intracellular Expression of CD83 and a Unique Profile of Phagocytic Receptors.
We investigated the possibility that immature DCs might phagocytose apoptotic cells via pathways distinct from macrophages. To clearly distinguish these cells, we characterized them phenotypically. Immature DCs are distinguished by the absence of both CD14, a macrophage restricted marker, and CD83, a maturation marker for DCs (30). We have extended the use of CD83, finding that immature DCs can be distinguished from both macrophages and mature DCs by their intracellular expression of CD83. Macrophages do not express CD83 intra- or extracellularly, whereas mature DCs express CD83 both intra- and extracellularly (Fig. 5).
|
vβ3 and CD36, which act as coreceptors for engulfment of apoptotic neutrophils and lymphocytes by macrophages (32, 33); and CD14, which has been implicated in the uptake of apoptotic cells by macrophages (34). While studying the immature DC populations, we identified a discrepancy in the expression of the
v and β3 integrin chains and investigated the possibility that
v was binding an alternate β chain. Using antibodies that recognize combined epitopes of the
vβ3 and the
vβ5 heterodimers, we noted the selective expression of
vβ5 on immature DCs (Fig. 6 A). As is true for most receptors involved in antigen uptake (11, 12), the expression of CD36,
vβ5, and mannose receptor on DCs is downregulated with maturation (Fig. 6 B, Table 1).
|
|
vβ5 and CD36 Mediate Phagocytosis of Apoptotic Cells in Immature DCs.
To demonstrate a direct role for
vβ5 in the recognition of apoptotic cells by immature DCs, we performed the phagocytosis FACS® assay in the presence of antibodies specific for
vβ5 (Fig. 7 A). In addition to the blocking observed using the mAb to
vβ5, blocking was also detected when using mAbs to
v, β5, and CD36. Blocking was not observed when isotype-matched mAbs were specific for β1, β3, or the transferrin receptor CD71. Note that control antibodies chosen recognized surface receptors present on the immature DCs (Fig. 7 A, Table 1). mAbs were tested in doses ranging from 10 to 80 µg/ml (data not shown). Maximal inhibition of phagocytosis of apoptotic cells was seen with mAbs specific for CD36,
v, and β5 at 50 µg/ml. The inhibition of phagocytosis of apoptotic cells by DCs was specific. We were unable to block the uptake of red fluorescent latex beads, a control particle, by DCs in the presence of these mAbs (Fig. 7 B). By histogram analysis, DCs phagocytose 1–6 particles per cell. mAbs to
vβ5 or
v did not alter the profile of these histogram plots (data not shown).
Although some inhibition of phagocytosis was observed when using
vβ3 this may be due in part to transdominance and/or the effect on the pool of free
v (35). For example, anti-
vβ3 antibodies suppress the intracellular signaling of the
5β1 integrin (36). Alternatively,
vβ3 and
vβ5 may be working cooperatively in the immature DCs. We therefore tested combinations of anti-
vβ3 and anti-
vβ5 but did not observe an increase in the inhibition of phagocytosis. The low receptor density of
vβ3 on DCs (average mean fluorescence intensity of 7 ± 2; Table 1) also makes it unlikely that this integrin heterodimer is involved in the engulfment of apoptotic cells by immature DCs.
Our data do not exclude a role for other receptors in the phagocytosis of apoptotic cells, e.g., the putative PS receptor or the lectin receptor (5). In fact, other receptors are probably involved, as blocking observed did not exceed 60% even when combinations of all relevant mAbs were tested (data not shown). CD14 is unlikely to be involved in the engulfment of apoptotic cells by DCs, as DCs do not express this receptor (Table 1). In macrophages, phagocytosis of apoptotic cells was inhibited by antibodies to
v, β3,
vβ3, and CD36 but not by antibodies to β1, β5, or
vβ5 (data not shown). This correlates with published data (6, 33).
| Discussion |
|---|
|
|
|---|
A sharp distinction was also demonstrated between immature DCs and macrophages in the handling of apoptotic material. Although macrophages are more efficient at phagocytosing apoptotic cells than immature DCs, they fail to induce virus-specific CTLs (7). In fact, they cannot even generate effective levels of peptide–MHC I complexes. In a short-term assay, influenza-specific CTLs could not kill macrophages cocultured with apoptotic cells. Therefore, macrophages degrade rather than cross-present the ingested apoptotic cells. Our findings probably do not conflict with the report of Bellone et al. (39), as their macrophages' were prepared from bone marrow–derived precursors by culturing the cells in GM-CSF for 7 d. This method is traditionally used to generate DCs from bone marrow (40). We believe that contaminating DCs account for the cross-presentation observed in their studies.
Additional evidence exists that macrophages process apoptotic cells differently from DCs and prevent an immune response. Two groups have demonstrated that phagocytosis of apoptotic cells suppresses a subsequent inflammatory response to LPS stimulation. The macrophage's cytokine profile is skewed toward the synthesis of IL-10, IL-13, and TGF-β, whereas the production of proinflammatory cytokines such as TNF-
, IL-1β, and IL-12 is downmodulated (41, 42). Therefore, the resolution of inflammation is dependent on at least two pathways for removal of apoptotic cells: via (a) macrophages, which subvert and suppress proinflammatory responses, and (b) DCs, which stimulate T cell responses that clear pathogens responsible for the induction of the apoptotic death.
The
vβ5 integrin receptor may be pivotal in the distinctive handling of apoptotic cells by immature DCs versus macrophages, in that its expression is restricted to the former. We suggest that the unique profile of receptors expressed by immature DCs affects trafficking of phagocytosed apoptotic cells, and consequently facilitates cross-presentation. We have previously shown that NH4Cl inhibits the ability of DCs to process antigen derived from apoptotic cells, suggesting that processing in an acidic vesicle (e.g., CIIVs or MIICs) is required (7). Indeed, class I MHC may interact with processed antigens in such a compartment, as MHC I molecules have been described in association with invariant chain (43) and can recycle from the cell surface to class II vesicles (44). Additionally, there may be as yet undescribed routes whereby antigens within vesicles can enter the classical endogenous pathway as described recently for antigens derived from the endoplasmic reticulum (45).
In contrast to our studies, Rubartelli et al. (46) have shown that immature DCs express high levels of the
vβ3 integrin but lack CD36. Their observations are hard to reconcile with data that indicates that
vβ3 and CD36 are both required for the engulfment of apoptotic cells by macrophages (33, 47). Furthermore, although they demonstrated inhibition of phagocytosis by DCs with anti-
v antibodies, they did not present phagocytosis data relevant to β3 or the
vβ3 heterodimer. However, it is possible that a different process is being studied, as phagocytosis in their hands is dependent on late stage Ann V+/PI+ apoptotic cells. Here, we discuss data relevant to the phagocytosis of early apoptotic cells with intact plasma membranes.
vβ5 and
vβ3 have both been described as important in angiogenesis, cell adhesion, migration, and now in their ability to phagocytose apoptotic cells.
vβ3 is critical in the phagocytosis of apoptotic cells in macrophages, where it acts in a cooperative way with CD36 and thrombospondin, collectively forming a molecular bridge' (47). Recently, it was reported that
vβ5 but not
vβ3 is critical for the engulfment of rod outer segments by CD36+ retinal pigment epithelial cells (48, 49). This phagocytic system is also inhibited by anti-CD36 antibodies, suggesting that
vβ5, like
vβ3, might cooperate with CD36. Taken together with our observations, thrombospondin, or possibly other soluble factors, may serve to bridge CD36,
vβ5, and the apoptotic cell.
Although similarities in function exist,
vβ5 can be distinguished from
vβ3 in its use of various ligands (e.g., vascular endothelial growth factor [VEGF] vs. basic fibroblast growth factor [bFGF]), by the requirements for activation, and by the intracellular signaling pathways (e.g., indirect activation of protein kinase C) (50). Also significant is the fact that the cytoplasmic domains of the two β chains are the portions that show the most considerable diversity (51). Thus, it is possible that the distinct use of the
vβ5 versus
vβ3 integrin receptors might account for the specialized functions of DCs in the route by which apoptotic material is trafficked and presented. In other words, differential expression of
vβ5 may be responsible for the ability of DCs to cross-present antigenic material derived from apoptotic cells, whereas macrophages scavenge and degrade such material.
| Acknowledgments |
|---|
Supported by National Institutes of Health (NIH) grants HL-42540 and EY-10967 (to S.F.A. Pearce and R.L. Silverstein); NIH MSTP grant GM-07793 (to M.L. Albert); NIH grant AI-39516, and grants from the SLE foundation (to N. Bhardwaj).
Submitted: 23 June 1998
Revised: 11 August 1998
| References |
|---|
|
|
|---|
1 Fadok VA, Savill JS, Haslett C, Bratton DL, Doherty DE, Campbell PA & Henson PM. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells, J Immunol, 1992, 149, 4029–4035.[Abstract]
2 Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation, Nature, 1980, 284, 555–556.[Medline]
3 Godman GC, Miranda AF, Deitch AD & Tanenbaum SW. Action of cytochalasin D on cells of established lines. Zeiosis and movement at the cell surface, J Cell Biochem, 1975, 64, 644–647.
4 Casciola-Rosen L, Anhalt G & Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes, J Exp Med, 1994, 179, 1317–1330.
5 Savill J. Phagocytic docking without shocking, Nature, 1998, 392, 442–443.[Medline]
6 Savill J. Recognition and phagocytosis of cells undergoing apoptosis, Br Med Bull, 1997, 53, 491–508.
7 Albert ML, Sauter B & Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I–restricted CTLs, Nature, 1998, 392, 86–89.[Medline]
8 Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay, J Exp Med, 1976, 143, 1283–1288.
9 Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D & Levitsky H. Role of bone marrow-derived cells in presenting MHC class I–restricted tumor antigens, Science, 1994, 264, 961–965.
10 Kurts C, Heath WR, Carbone FR, Allison J, Miller JFAP & Kosaka H. Constitutive class I–restricted exogenous presentation of self antigens in vivo, J Exp Med, 1996, 184, 923–930.
11 Banchereau J & Steinman RM. Dendritic cells and the control of immunity, Nature, 1998, 392, 245–252.[Medline]
12 Sallusto F & Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate antigen in the MHC class II compartment. Downregulation by cytokines and bacterial products, J Exp Med, 1995, 182, 389–400.
13 Sallusto F & Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor
, J Exp Med, 1994, 179, 1109–1118.
14 Pierre P, Turley SJ, Gatti E, Hull M, Meltzer J, Mirza A, Inaba K, Steinman RM & Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells, Nature, 1997, 388, 787–792.[Medline]
15 Inaba K, Inaba M, Naito M & Steinman RM. Dendritic cell progenitors phagocytose particulates, including Bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo, J Exp Med, 1993, 178, 479–488.
16 Reis e Sousa C, Stahl PD & Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro, J Exp Med, 1993, 178, 509–519.
17 Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S et al.. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro, J Exp Med, 1994, 180, 1849–1860.
18 Bender A, Sapp M, Schuler G, Steinman RM & Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood, J Immunol Methods, 1996, 196, 121–135.[Medline]
19 Romani N, Reider D, Heuer M, Ebner S, Eibl B, Niederwieser D & Schuler G. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability, J Immunol Methods, 1996, 196, 137–151.[Medline]
20 Sallusto F, Nicolo C, De Maria R, Corinti S & Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells, J Exp Med, 1996, 184, 2411–2416.
21 Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, Durand I & Banchereau J. Activation of human dendritic cells through CD40 cross-linking, J Exp Med, 1994, 180, 1263–1272.
22 Rieser C, Bock G, Klocker H, Bartsch G & Thurnher M. Prostaglandin E2 and tumor necrosis factor
cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production, J Exp Med, 1997, 186, 1603–1608.
23 Hess KL, Babcock GF, Askew DS & Cook-Mills JM. A novel flow cytometric method for quantifying phagocytosis of apoptotic cells, Cytometry, 1998, 27, 145–152.[Medline]
24 Bhardwaj N, Bender A, Gonzalez N, Bui LK, Garrett MC & Steinman RM. Influenza virus–infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+T cells, J Clin Invest, 1994, 94, 797–807.[Medline]
25 Fesq H, Bacher M, Nain M & Gemsa D. Programmed cell death (apoptosis) in human monocytes infected by influenza virus, Immunobiology, 1994, 190, 175–182.[Medline]
26 Hofmann P, Sprenger H, Kaufmann A, Bender A, Hasse C, Nain M & Gemsa D. Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response, J Leukocyte Biol, 1997, 612, 408–414.
27 Steinkamp JA, Wilson JS, Saunders GC & Stewart CC. Phagocytosis: flow cytometric quantitation with fluorescent microspheres, Science, 1981, 215, 64–66.
28 Gotch F, Rothbard J, Howland K, Townsend A & McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2, Nature, 1987, 326, 881–882.[Medline]
29 Silverstein RL, Baird M, Lo S & Yesner LM. Sense and antisense cDNA transfection of CD36 in melanoma cells. Role of CD36 as a thrombospondin receptor, J Biol Chem, 1992, 267, 16607–16612.
30 Zhou L-J & Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily, J Immunol, 1995, 154, 3821–3835.[Abstract]
31 De Togni P, Goellner J, Ruddle NH, Streeter PR, Fick A, Mariathasan S, Smith SC, Carlson R, Shornick LP, Strauss-Schoenberger J et al.. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin, Science, 1994, 264, 703–707.
32 Savill JS, Dransfield I, Hogg N & Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis, Nature, 1990, 343, 170–173.[Medline]
33 Ren Y, Silverstein RL, Allen J & Savill J. CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis, J Exp Med, 1995, 181, 1857, (Abstr.), .
34 Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL & Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptopic cells, Nature, 1998, 392, 505–509.[Medline]
35 Diaz-Gonzalez F, Forsyth J, Steiner B & Ginsberg MH. Trans-dominant inhibition of integrin function, Mol Biol Cell, 1996, 7, 1939–1951.[Abstract]
36 Blystone SD, Graham IL, Lindberg FP & Brown EJ. Integrin alpha v beta 3 differentially regulates adhesive and phagocytic function of the fibronectin receptor alpha 5 beta 1, J Cell Biol, 1994, 127, 1129–1137.
37 Carbone FR, Moore MW, Sheil JM & Bevan MJ. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides, J Exp Med, 1988, 167, 1767–1779.
38 Heath WR, Kurts C, Miller JFAP & Carbone F. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens, J Exp Med, 1998, 187, 1549–1553.
39 Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C & Manfredi AA. Processing of engulfed apoptotic bodies yields T cell epitopes, J Immunol, 1997, 159, 5391–5399.[Abstract]
40 Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S & Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor, J Exp Med, 1992, 176, 1693–1702.
41 Voll RE, Herrmann M, Roth EA, Stach C & Kalden JR. Immunosuppressive effects of apoptotic cells, Nature, 1997, 390, 350–351.[Medline]
42 Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY & Henson PM. Macrophages that have ingested apoptosis cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF, J Clin Invest, 1998, 101, 890–898.[Medline]
43 Sugita M & Brenner MB. Association of the invariant chain with major histocompatibility complex class I molecules directs trafficking to endocytic compartments, J Biol Chem, 1995, 270, 1443–1448.
44 Jondal M, Schirmbeck R & Reimann J. MHC class-I restricted CTL responses to exogenous antigens, Immunity, 1996, 5, 295–302.[Medline]
45 Snyder HL, Bacik I, Bennink JR, Kearns G, Behrens TW, Bachi T, Orlowski M & Yewdell JW. Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing, J Exp Med, 1997, 186, 1087–1098.
46 Rubartelli A, Poggi A & Zocchi MR. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the
vβ3 integrin and requires intracellular and extracellular calcium, Eur J Immunol, 1997, 27, 1893–1900.[Medline]
47 Savill J, Hogg N, Ren Y & Hasslet C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis, J Clin Invest, 1992, 90, 1513–1522.[Medline]
48 Ryeom SW, Sparrow JR & Silverstein RL. CD36 participates in the phagocytosis of rod outer segments by retinal pigment epithelium, J Cell Sci, 1996, 109, 387–395.[Abstract]
49 Finnemann SC, Bonilha VL, Marmorstein AD & Rodriguez-Boulan E. Phagocytosis of rod outer segments by retinal pigment epithelial cells requires alpha(v) beta5 integrin for binding but not for internalization, Proc Natl Acad Sci USA, 1997, 94, 12932–12937.
50 Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA & Cheresh DA. Definition of two angiogenic pathways by distinct
vintegrins, Science, 1995, 270, 1500–1502.
51 McClean JW, Vestal DJ, Cheresh DA & Bodary SC. cDNA sequence of the human integrin β5subunit, J Biol Chem, 1990, 265, 17126–17131.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|